Drug repurposing of dermatologic medications to treat coronavirus disease 2019: Science or fiction?
- 2 February 2021
- journal article
- research article
- Published by Elsevier BV in Clinics in Dermatology
- Vol. 39 (3), 430-445
- https://doi.org/10.1016/j.clindermatol.2021.01.020
Abstract
No abstract availableKeywords
This publication has 160 references indexed in Scilit:
- Anti-inflammatory effect of thalidomide in paraquat-induced pulmonary injury in miceInternational Immunopharmacology, 2013
- Innovative Use of DapsoneDermatologic Clinics, 2010
- Rituximab: Mechanism of ActionSeminars in Hematology, 2010
- Microtubule-mediated NF-κB activation in the TNF-α signaling pathwayExperimental Cell Research, 2009
- Acute generalized exanthematous pustulosis induced by hydroxychloroquine: Three cases and a review of the literatureClinical Therapeutics, 2008
- Polymorphonuclear leukocyte motility in vitro: IV. Colchicine inhibition of chemotactic activity formation after phagocytosis of urate crystalsArthritis & Rheumatism, 2008
- Thalidomide: dermatological indications, mechanisms of action and side-effectsBritish Journal of Dermatology, 2005
- In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquineBiochemical and Biophysical Research Communications, 2004
- The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell culturesClinical and Experimental Immunology, 1995
- Colchicine. New uses of an old, old drugArchives of Dermatology, 1982